Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2017 2
2018 1
2019 15
2020 13
2021 8
2022 6
2023 11
2024 13
2025 29
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 41720504

101 results

Results by year

Filters applied: . Clear all
Page 1
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, Cebulla K, Frey R, Fu DJ, Ito T, Kambarov Y, Llorca PM, Oliveira-Maia AJ, Messer T, Mulhern-Haughey S, Rive B, von Holt C, Young AH, Godinov Y; ESCAPE-TRD Investigators. Reif A, et al. N Engl J Med. 2023 Oct 5;389(14):1298-1309. doi: 10.1056/NEJMoa2304145. N Engl J Med. 2023. PMID: 37792613 Free article. Clinical Trial.
Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.
Vieta E, Ahmed N, Arango C, Cleare AJ, Demyttenaere K, Dold M, Ito T, Kambarov Y, Krüger S, Llorca PM, McIntyre RS, Sani G, von Holt C, Rive B. Vieta E, et al. Eur Neuropsychopharmacol. 2025 Apr;93:29-39. doi: 10.1016/j.euroneuro.2024.12.013. Epub 2025 Feb 8. Eur Neuropsychopharmacol. 2025. PMID: 39923271 Free article. Clinical Trial.
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial.
Kerr-Gaffney J, Zenasni Z, Goldsmith K, Yaziji N, Jin H, Colasanti A, Geddes J, Kessler D, McAllister-Williams RH, Young AH, Barrera A, Marwood L, Taylor RW, Tee H, Cleare AJ; LQD Study Group. Kerr-Gaffney J, et al. Health Technol Assess. 2025 May;29(12):1-118. doi: 10.3310/YQVF5347. Health Technol Assess. 2025. PMID: 40350798 Free PMC article. Clinical Trial.
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Popova V, et al. Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109201 Clinical Trial.
101 results